RICT 2019

Interfacing Chemical Biology and Drug Discovery

55th International Conference on Medicinal Chemistry
55èmes Rencontres Internationales de Chimie Thérapeutique

 Nantes, France    July 3-5, 2019

Plenary Speakers

PL16: Straightforward Conversion of Peptides into Bioactive Lactam-Based Foldamers

Prof. Muriel AMBLARD
Prof. Muriel AMBLARD
CNRS-UNIVERSTY OF MONTPELLIER I, Montpellier, France
Read more

PL09: Chemical Physiology of Antibody Conjugates and Natural Products

Dr Goncalo BERNARDES
Dr Goncalo BERNARDES
INSTITUTO DE MEDICINA MOLECULAR, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom
Read more

PL13: Complex Glycans in Health and Disease

Prof. Geert-Jan BOONS
Prof. Geert-Jan BOONS
UTRECHT UNIVERSITY, Utrecht, The Netherlands
Read more

PL18: Modulating Different Components of the Ubiquitin System with Small Molecules and Cyclic Peptides

Prof. Ashraf BRIK
Prof. Ashraf BRIK
TECHNION-ISRAEL INSTITUTE OF TECHNOLOGY, Haifa, Israel
Read more

PL07: The Influence of Free Ligand Conformations on Mcl-1 PPI Inhibition

Dr Rodrigo CARBAJO
Dr Rodrigo CARBAJO
ASTRAZENECA, Cambridge, United Kingdom
Read more

PL12: Carbohydrate-Lectin Interactions - What Makes Them Unique?

Prof. Dr Beat ERNST
Prof. Dr Beat ERNST
UNIVERSITY OF BASEL, Basel, Switzerland
Read more

PL03: Quo Vadis Small Molecule Cancer Therapeutics?

Dr Ingo HARTUNG
Dr Ingo HARTUNG
BAYER HEALTHCARE, Berlin, Germany
Read more

PL15: Identification of S 64315, a Potent and Selective Mcl-1 Inhibitor through Fragment-based Drug Discovery

Dr Andras KOTSCHY
Dr Andras KOTSCHY
SERVIER RESEARCH INSTITUTE OF MEDICINAL CHEMISTRY, Budapest, Hungary
Read more

PL11: Increasing Brain Exposure of Therapeutic Antibodies

Dr Dominique LESUISSE
Dr Dominique LESUISSE
SANOFI, Chilly-Mazarin, France
Read more

PL04: Massively Multi-target Profile-QSAR: IC50 Predictions Comparable to 4-Concentration Experiments for most Novartis Assays

Dr Eric MARTIN
Dr Eric MARTIN
NOVARTIS, Emeryville, United States
Read more

PL01: What Makes a Great Medicinal Chemist: Some Fresh Thoughts

Dr Mark MURCKO
Dr Mark MURCKO
RELAY THERAPEUTICS, Cambridge, United States
Read more

PL19: Cysteine Arylation to Engineer, Deliver, and Discover Proteins

Prof. Bradley Lether PENTELUTE
Prof. Bradley Lether PENTELUTE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States
Read more

PL06: Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

Dr Hasane RATNI
Dr Hasane RATNI
F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland
Read more

PL17: Chemical Biology of mRNA Modifications

Prof. Andrea RENTMEISTER
Prof. Andrea RENTMEISTER
UNIVERSITY OF MÜNSTER, Münster, Germany
Read more

PL10: Click-Cleavable Antibody-Drug Conjugates

Dr Marc ROBILLARD
Dr Marc ROBILLARD
TAGWORKS PHARMACEUTICALS, Eindhoven, The Netherlands
Read more

PL02: Reprogramming the Reactivity of Iron in Cancer

Dr Raphaël RODRIGUEZ
Dr Raphaël RODRIGUEZ
INSTITUT CURIE, Paris, France
Read more

PL05: Automated Syntheses Planning and its Implications for Drug Design

Mr Marwin SEGLER
Mr Marwin SEGLER
BENEVOLENTAI, London, United Kingdom
Read more

PL20: Pierre Fabre Award Lecture - Click Chemistry with Mesoionics: New Tools for Chemical Biology

Dr Frédéric TARAN
Dr Frédéric TARAN
CEA/SACLAY, Gif-sur-Yvette, France
Read more

PL08: Paul Ehrlich Award Lecture - Chemotype - Phenotype - Target

Prof. Herbert WALDMANN
Prof. Herbert WALDMANN
MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany
Read more

PL14: Unlocking Drug Discovery Power through Collaborative Efforts between Academia and CRO : Bringing Novel Tankyrase Inhibitors towards the Clinic

Dr Anita WEGERT
Dr Anita WEGERT
MERCACHEM-SYNCOM, Nijmegen, The Netherlands
Read more

Keynote Speakers

KL01: Therapeutic Potential of Macrocyclic ALK2 Inhibitors

Dr Pascal BENDERITTER
Dr Pascal BENDERITTER
ONCODESIGN, Dijon, France
Read more

KL03: Nanofitin Modules Platform: Go Multispecific, Go Multiparatopic !

Dr Anne CHEVREL
Dr Anne CHEVREL
AFFILOGIC, Nantes, France
Read more

KL02: Tackling a Unique S1 Protease by SBDD - Highly Potent & Selective Factor D Inhibitors - Age-Related Macular Generation (AMD)

Dr Edwige LORTHIOIS
Dr Edwige LORTHIOIS
NOVARTIS, Basel, Switzerland
Read more